Charles River Laboratories International Stock News

Charles River Laboratories International (NYSE:CRL) and Absci (NASDAQ:ABSI) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Profitability This table compares Charles River Laboratories International and Abscis net margins, return on equity []

Brokerages predict that Charles River Laboratories International, Inc. (NYSE:CRL) will announce earnings of $2.42 per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Charles River Laboratories Internationals earnings, with the lowest EPS estimate coming in at $2.39 and the highest estimate coming in at $2.45. Charles River Laboratories []

Charles River (CRAI) stock has been benefiting from consecutive better-than-expected top- and bottom-line performances, and shareholder-friendly moves.

The Formulation Development Outsourcing Market research report is a point-by-point investigation of the Formulation Development Outsourcing industry that represents considerable authority in recognizing the development capability of the global Formulation Development Outsourcing Market and potential opportunities in the market. Secondary

Berman Capital Advisors LLC boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 243 shares of the medical research companys stock after purchasing an additional 44 shares during []

Charles River Laboratories International (NYSE:CRL) had its target price hoisted by Deutsche Bank Aktiengesellschaft from $354.00 to $409.00 in a research report sent to investors on Tuesday, The Fly reports. They currently have a buy rating on the medical research companys stock. CRL has been the topic of a number of other reports. Morgan Stanley []

Shilanski & Associates Inc. purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, HoldingsChannel.com reports. The firm purchased 3,297 shares of the medical research companys stock, valued at approximately $1,361,000. A number of other large investors have also recently added to or reduced their stakes in CRL. Assetmark Inc. []

Fragasso Group Inc. trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,535 shares of the medical research companys stock after selling 192 shares during the quarter. Charles River []

TPG Financial Advisors LLC lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 21.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 942 shares of the medical research companys stock after acquiring an additional 165 shares during the period. TPG Financial Advisors LLCs holdings in Charles River Laboratories International were worth []

Strong balance sheet and measures to drive shareholders' value boost Charles River (CRAI).

Charles River Laboratories Inte with ticker code (CRL) have now 11 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 465 and 354 with the average target price sitting at 438.73. Now with the previous closing price of 385.91 this indicates there is a potential upside of 13.7%. The day 50 moving average is 410.18 while the 200 day moving average is 390.9. The market cap for the company is $19,406m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="CRL" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Charles River Laboratories International, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

DUBLIN--(BUSINESS WIRE)--The "Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com''s offering. The global mice model market is expected to register a CAGR of 6.8% over the forecast period, 2021-2026. Companies Mentioned Allentown, LLC Charles River Laboratories International Inc. ENVIGO Genoway Harbour Biomed Horizon Discovery Group PLC (Sage Labs Inc.) Ingenious Targeting Laboratory Janvier Labs Ozgene Pty Ltd. PolyGe

Overview of Global Biotechnology Market: The market dynamics study of an influential Biotechnology Market report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. Important industry trends, Market size,

Equities analysts forecast that Charles River Laboratories International, Inc. (NYSE:CRL) will post sales of $883.93 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Charles River Laboratories Internationals earnings, with the highest sales estimate coming in at $887.30 million and the lowest estimate coming in at $875.12 []

Confluence Investment Management LLC cut its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 32.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,409 shares of the medical research companys stock after selling 59,972 shares during the quarter. Confluence Investment []